| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic we...
																	
																	iBio shares rose sharply after announcing upcoming presentations on its obesity treatment candidate at two industry conferences.